Tango Therapeutics, Inc. Increase (Decrease) in Accounts Receivable
Tango Therapeutics, Inc. (TNGX) reported Increase (Decrease) in Accounts Receivable of -$2.00 million for the 12-month period ending 2023-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-03-05
- Tango Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2023-12-31 was $0.00.
- Tango Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2023-09-30 was $0.00.
- Tango Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2023-06-30 was $0.00.
- Tango Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2023-03-31 was -$2.00M.
- Tango Therapeutics, Inc. increase (decrease) in accounts receivable for fiscal 2023 was -$2.00M.
- Tango Therapeutics, Inc. increase (decrease) in accounts receivable for fiscal 2020 was $2.00M.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 9 month as first filed | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $0.00 derived: sum of 2 quarters · filed 2026-03-05 | $0.00 derived: sum of 3 quarters · filed 2026-03-05 | -$2.00M 10-K · filed 2026-03-05 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $0.00 derived: sum of 2 quarters · filed 2024-11-06 | -$2.00M 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$2.00M 10-Q · filed 2024-08-07 | |||
| 2023-03-31 | -$2.00M 10-Q · filed 2024-05-08 | ||||
| 2021-09-30 | -$6.00M 10-Q · filed 2022-11-10 | $6.00M 10-Q · filed 2021-11-09 | |||
| 2020-12-31 | $2.00M 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |